Strategy+ Advises Pfizer (NYSE: PFE) on Merger of Upjohn and Mylan (NASDAQ: MYL) into Viatris (NASDAQ: VTRS)

By

Strategy+ originated and advised Pfizer (NYSE: PFE) on the $12 Billion merger of Upjohn and Mylan (NASDAQ: MYL) into Viatris (NASDAQ: VTRS).

Strategy+ advised one of the world’s premier biopharmaceutical companies Pfizer (NYSE: PFE) on the merger of its off-patent branded and generic established medicines business, Upjohn with Mylan (NASDAQ: MYL). The deal resulted in the creation of a new global pharmaceutical company, Viatris (NASDAQ: VTRS). The definitive agreement was announced July 29, 2019. The all-stock, Reverse Morris Trust transaction was valued at $12 Billion.

‍

Read the transaction press release

Note to Editors: This press release may contain forward-looking statements regarding Strategy+’s intentions and interests. These statements are based on current expectations and assumptions that are subject to risks and uncertainties. Actual results may differ materially from those expressed or implied in these statements. The firm does not undertake any obligation to update or revise any forward-looking statements, whether as a result of new information, future events, or otherwise.

strategyadd.com (the “Strategy Group LLC Website”) is a website operated by Strategy Group LLC, a privately held Florida limited liability company. Strategy Group LLC is not a registered broker-dealer. Strategy Group LLC provides strategic advisory and consulting services strictly in connection with mergers and acquisitions and capital raising. Strategy Group LLC does not act as a broker-dealer, does not engage in securities transactions, and does not receive transaction-based compensation. Strategy Group LLC’s services are limited to strategic advisory, and it does not perform or facilitate securities sales or trades.